Eli Lilly reported that its experimental drug retatrutide produced greater average weight reduction than existing obesity treatments in a phase-three trial involving 2,339 adults with obesity or overweight and related health conditions but no diabetes. Participants receiving the highest 12-milligram weekly dose lost an average of 28.3 percent of their starting body weight, or about 70 pounds, over 80 weeks. Nearly half achieved at least 30 percent loss, and more than 65 percent lowered their body-mass index below the obesity threshold. Lower doses also yielded substantial results, with the 9-milligram group averaging 25.9 percent loss and the 4-milligram group 19 percent. The medication acts on three hormone pathways, including glucagon, which distinguishes it from current GLP-1 and GIP-based options. Common side effects such as nausea, diarrhea, constipation and vomiting increased with dose but remained consistent with the drug class. Researchers noted meaningful improvements in cardiovascular risk markers including cholesterol, triglycerides and blood pressure. The findings suggest retatrutide may set a new benchmark for pharmacological weight management, though long-term safety data are still being collected.
